ANAPTYSBIO, INC

Clinical-stage biotech developing immunology therapies for autoimmune and inflammatory diseases.

ANAB | NDAQ

Overview

Corporate Details

ISIN(s):: US0327241065
LEI:
Country:: United States of America
Address:: 10770 WATERIDGE CIRCLE, SUITE 210, 92121 SAN DIEGO
Website:: https://www.anaptysbio.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

AnaptysBio, Inc. is a clinical-stage biotechnology company that develops innovative immunology therapeutics for autoimmune and inflammatory diseases. The company's pipeline includes rosnilimab, a pathogenic T cell depleter in Phase 2b trials for rheumatoid arthritis, and ANB033, a CD122 antagonist. AnaptysBio has announced plans to separate its biopharmaceutical operations from its royalty assets into two independent, publicly traded companies by year-end 2026 to align with different investor strategies.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all ANAPTYSBIO, INC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ANAPTYSBIO, INC

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for ANAPTYSBIO, INC via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Cantourage Group SE A European platform producing and distributing medical cannabis products to pharmacies.	Germany	HIGH
CAPRICOR THERAPEUTICS, INC. Develops cell and exosome-based therapeutics for rare diseases like Duchenne muscular dystrophy.	United States of America	CAPR
CAREGEN CO.,LTD. Develops patented peptides and growth factors for medical aesthetics, pharma, and anti-aging markets.	South Korea	214370
Caribou Biosciences, Inc. Uses CRISPR genome editing to create off-the-shelf CAR-T cell therapies for cancer.	United States of America	CRBU
Carisma Therapeutics Inc. Developing engineered macrophage (CAR-M) therapies for solid tumors and autoimmune diseases.	United States of America	CARM
Cartesian Therapeutics, Inc. Pioneering mRNA-engineered cell therapies to treat autoimmune diseases.	United States of America	RNAC
CASI Pharmaceuticals, Inc. Develops and commercializes drugs for oncology, transplant, and autoimmune disease.	United States of America	CASI
CASSAVA SCIENCES INC Clinical-stage biotech developing oral drug simufilam for CNS disorders like TSC-related epilepsy.	United States of America	SAVA
CATALYST PHARMACEUTICALS, INC. Advancing therapies for rare neuromuscular and neurological diseases like LEMS.	United States of America	CPRX
cbdMD, Inc. Produces & distributes lab-tested CBD wellness products for people and pets.	United States of America	YCBD